Revision as of 19:12, 1 April 2019 by Wgalvin85 (talk | contribs) (General)


  • Type: Antibiotic, Cephalosporin (fifth generation)
  • Dosage Forms: IV
  • Common Trade Names: Teflaro

Adult Dosing

  • Pneumonia, Community-acquired: IV: 600 mg every 12 hours for 5 to 7 days
  • Skin and skin structure infection: IV: 600 mg every 12 hours for 5 to 14 days

Pediatric Dosing

Special Populations

  • Pregnancy Rating:
    • Adverse events have been observed in animal studies
  • Lactation:
    • Unknown if excreted in breast milk. Manufacturer recommends to use caution when giving to nursing women.
  • Renal Dosing
    • Adult
      • CrCl > 50 mL/minute: No dosage adjustment necessary
      • CrCl > 30 to ≤ 50 mL/minute: 400 mg every 12 hours
      • CrCl ≥ 15 to ≤ 30 mL/minute: 300 mg every 12 hours
      • CrCl < 15 mL/minute: 200 mg every 12 hours
      • ESRD patients on hemodialysis: 200 mg every 12 hours; dose given after hemodialysis on dialysis days
    • Pediatric
      • ≥ 2 months to < 18 years of age
        • CrCl > 50 mL/minute/1.73 m²: No adjustment necessary
        • CrCl ≤ 50 mL/minute/1.73 m²: Insufficient data, use with caution, dosing adjustment may be necessary
      • ≥ 18 years of age - same as adult dosing
  • Hepatic Dosing
    • Adult
      • No dosage adjustment in manufacturer's labeling. Has not been studied.
    • Pediatric
      • No dosage adjustment in manufacturer's labeling. Has not been studied.


  • Allergy to class/drug

Adverse Reactions




  • Half-life:
  • Metabolism:
  • Excretion:
  • Mechanism of Action:

Antibiotic Sensitivities[1]

Group Organism Sensitivity
Gram Positive Strep. Group A, B, C, G S
Strep. Pneumoniae S
Viridans strep S
Strep. anginosus gp X1
Enterococcus faecalis S
Enterococcus faecium X1
Staph. Epidermidis S
C. jeikeium X1
L. monocytogenes X1
Gram Negatives N. gonorrhoeae I
N. meningitidis S
Moraxella catarrhalis S
H. influenzae S
E. coli S
Klebsiella sp S
E. coli/Klebsiella ESBL+ R
E coli/Klebsiella KPC+ R
Enterobacter sp, AmpC neg S
Enterobacter sp, AmpC pos R
Serratia sp S
Serratia marcescens X1
Salmonella sp S
Shigella sp S
Proteus mirabilis S
Proteus vulgaris S
Providencia sp. S
Morganella sp. S
Citrobacter freundii X1
Citrobacter diversus S
Citrobacter sp. S
Aeromonas sp S
Acinetobacter sp. X1
Pseudomonas aeruginosa R
Burkholderia cepacia R
Stenotrophomonas maltophilia R
Yersinia enterocolitica X1
Francisella tularensis X1
Brucella sp. X1
Legionella sp. R
Pasteurella multocida X1
Haemophilus ducreyi X1
Vibrio vulnificus X1
Misc Chlamydophila sp X1
Mycoplasm pneumoniae X1
Rickettsia sp X1
Mycobacterium avium X1
Anaerobes Actinomyces X1
Bacteroides fragilis R
Prevotella melaninogenica X1
Clostridium difficile X1
Clostridium (not difficile) X1
Fusobacterium necrophorum X1
Peptostreptococcus sp. X1


  • S susceptible/sensitive (usually)
  • I intermediate (variably susceptible/resistant)
  • R resistant (or not effective clinically)
  • S+ synergistic with cell wall antibiotics
  • U sensitive for UTI only (non systemic infection)
  • X1 no data
  • X2 active in vitro, but not used clinically
  • X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
  • X4 active in vitro, but not clinically effective for strep pneumonia

See Also


  1. Sanford Guide to Antimicrobial Therapy 2014

Ceftaroline: Drug information. UpToDate. www.uptodate.com. Accessed April 1, 2019.